Nexstim logo

Addition to the proposals of the Nomination Committee to the Annual Shareholder’s Meeting of Nexstim Plc.

22 March 2017

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients with the use of non-invasive brain stimulation, announces that the Nomination Committee will propose to the annual general meeting of Nexstim Plc that Tomas Holmberg will be elected as the fifth member of the Board of Director’s. Tomas Holmberg’s CV can be found from



Martin Jamieson, Chairman and CEO


For further information please visit or contact:


Nexstim                                                                                                                                    +447715163942

Martin Jamieson, Chairman and CEO                                         


UB Securities Oy (Certified Adviser)                                                                         +358 (0)9 2538 0246


Citigate Dewe Rogerson                                                                                               +44 (0)207 2821066

Katja Stout                                                                                              


About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit





Back to Press Releases